Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Akeso Presents Positive Trial Results from PD-1/CTLA-4 Candidate

publication date: Nov 11, 2019

Akeso Biopharma of Zhongshan presented results from an Australian Phase I trial of a novel immunotherapy, AK104, a tetrameric bispecific antibody targeting both PD-1 and CTLA-4. The trial enrolled patients with advanced solid tumors. In 25 patients, AK104 produced an overall response rate of 24% and an acceptable safety profile. The company has expanded Phase Ib/II trials of AK104 to include China and the US. Last week, Akeso announced a $150 million Series D funding to advance its portfolio of 18 mAbs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China